Health Catalyst (HCAT) News Today

Health Catalyst, Inc. (HCAT) shares have declined today as analyst downgrades and lowered guidance outweighed solid Q2 results. Key developments include:

• Positive Sentiment: Q2 revenue of $80.7 million and adjusted EBITDA of $9.3 million beat company guidance Press Release
• Positive Sentiment: EPS of $0.04 and revenues topped Zacks consensus estimates of $0.03 per share Zacks
• Neutral Sentiment: Q2 sales were in line with estimates, though shares dipped despite matching top‐line forecasts MSN
• Neutral Sentiment: Stifel Nicolaus cut its price target to $4.50 (from $5.50) and maintained a “hold” rating Benzinga
• Neutral Sentiment: Cantor Fitzgerald reaffirmed a “neutral” rating while lowering its target to $4.00 (from $9.00) Benzinga, Briefing.com
• Neutral Sentiment: CEO Dan Burton announced he will step down in June 2026, triggering a leadership transition PR Newswire
• Negative Sentiment: Management cut its full-year 2025 revenue outlook to $310 million (vs. $334 million prior) and EPS guidance below Street forecasts
• Negative Sentiment: Q3 revenue guidance was lowered to $75 million versus consensus of $84.9 million
• Negative Sentiment: Analysts at Cantor downgraded the stock following the FY outlook cut MSN
• Negative Sentiment: Q2 EPS missed consensus—reported a loss of $0.08 per share vs. $0.05 expected Q2 Press Release